Searchable abstracts of presentations at key conferences in endocrinology

ea0063ep101 | Pituitary and Neuroendocrinology | ECE2019

Pituitary apoplexy and transient hypopituitarism

Rego Teresa , Cerqueira Luis , Agapito Ana

Introdution: Pituitary apoplexy (PA) is a rare clinical syndrome caused by sudden hemorrhage or infarction of the pituitary gland. PA may be the form of presentation of a pituitary tumor or occur during follow-up of a previously diagnosed macroadenoma. A high suspicion índex is required to establish a timely diagnosis.Case report: A 54-year-old man was referred to Endocrinology department (04/2015) due to a pituitary macroadenoma. He reported sexual...

ea0081p675 | Pituitary and Neuroendocrinology | ECE2022

Central diabetes insipidus following immunization with BNT162b2 mRNA Covid-19 vaccine

Bouca Bruno , Roldao Marisa , Bogalho Paula , Cerqueira Luis , Silva-Nunes Jose

Introduction: The endocrine complications of COVID-19 remain largely unknown. Cases of central diabetes insipidus (CDI) have been reported after COVID-19, with hypophysitis being the most likely cause. COVID-19 vaccines potential adverse effects may mimetize some of these complications. We present a case of a woman who developed CDI one week after the 2 nd dose of BNT162b2 mRNA COVID-19 vaccine.Case Report: Female patient, 37 years old, with rheumatoid a...

ea0090ep703 | Pituitary and Neuroendocrinology | ECE2023

Silent pituitary macroadenomas – clinical behavior and prognosis

Manique Ines , Amaral Sara , Palha Ana , Cortez Luisa , Cerqueira Luis , Sagarribay Amets , Silva-Nunes Jose

Introduction: A third of pituitary adenomas are non-functioning. Classification depends on adenohypophyseal hormones expression and transcription factors.Aim: Characterize silent pituitary macroadenomas cases regarding their clinical data, treatment, histopathology and prognosis.Methods: We revised clinical process of patients followed in CHULC. Cases with non-access to clinical follow-up registries or exams were excluded.<p cl...

ea0063p716 | Pituitary and Neuroendocrinology 2 | ECE2019

Giant prolactinoma: a case with thirty-five years of follow-up

Palha Ana , Sagarribay Amets , Fonseca Fernando , Cerqueira Luis , Mafra Manuela , Agapito Ana

Introduction: Giant prolactinomas are rare pituitary tumours, more frequently found in men (9:1), defined by an unusually large size (>4 cm), significant extrasellar extension and prolactin levels above 1000 ng/ml. Although dopamine agonists (DA) are the first-line treatment, combined therapy with DA and surgery, or rarely radiotherapy, may be necessary particularly when tumour volume control is not achieved.Case presentation: A 60-year-old woman, wa...

ea0049ep1000 | Pituitary - Clinical | ECE2017

Spindle cell oncocytoma of adenohypophysis: report of a rare pituitary tumor

Pontinha Carlos Marques , Mafra Manuela , Cerqueira Luis , Sagarribay Amets , Fonseca Fernando , Agapito Ana

Introduction: Pituitary adenomas represent 95% of all sellar masses. Spindle cell oncocytoma (SCO), a rare histopathological entity (0.4% of all sellar tumours), clinically presents as a non-functional pituitary adenoma. According to WHO 2016 Classification of Tumours of the CNS it is a Grade l tumour, but prognosis remains uncertain since recurrence is frequently seen among the few cases reported.Clinical case: A 59 year-old man presented with progressi...

ea0049ep1062 | Pituitary - Clinical | ECE2017

T2-weighted MRI signal and response to somatostatin analogs in acromegaly

Cerqueira Luis , Palha Ana , Cortez Luisa , Sagarribay Amets , Fonseca Fernando , Agapito Ana

Introduction: somatostatin analogs (SSA) are largely prescribed in acromegalic patients, whether as adjuvant or primary therapy. Response is variable and seems dependent of histological subtype. Intensity T2 signal in MRI has been related to granulation patern and accordingly with response to SSA.Objective: To evaluate whether T2 MRI signal is correlated with effectiveness of SSAMaterial and methods: Retrospective analysis of acrom...

ea0090p135 | Pituitary and Neuroendocrinology | ECE2023

Prolactinomas under high doses cabergoline in portuguese patients: The Resistant Prolactinoma Study

Manique Ines , Benido Silva Vania , Carvalho Davide , Marques Olinda , Nobre Ema , Joao Bugalho Maria , Palha Ana , Ribeiro Isabel , Pereira Josue , Almeida Rui , Sagarribay Amets , Cerqueira Luis , Amaral Claudia

Background: In 15% of prolactinomas there is dopamine agonist(DA) resistance. The clinical characteristics, the best diagnostic and therapeutic management of these cases have not been established so far.Aim: To characterize patients taking a high dose cabergoline(≥ 3mg/week) and then describe clinical, biochemical and imaging features of cabergoline-resistant cases.Methods: Retrospective study with 5 centers representing the ...